Dr. Chavez on Combination of Ibrutinib Plus Ublituximab in CLL

Julio Chavez, MD
Published: Thursday, Sep 07, 2017



Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the potential with the combination of ibrutinib (Imbruvica) and ublituximab (TGR-1101) in patients with chronic lymphocytic leukemia (CLL).

The combination was explored in the GENUINE study, results of which were presented at the 2017 ASCO Annual Meeting. Ublituximab is a monoclonal antibody that is similar to obinutuzumab (Gazyva), Chavez explains. It has shown good activity as a single agent and also in combination with other drugs.

As seen in other clinical trials of combinations with ibrutinib, Chavez says that adding ibrutinib to a monoclonal antibody like ublituximab could lead to better outcomes.
 


Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the potential with the combination of ibrutinib (Imbruvica) and ublituximab (TGR-1101) in patients with chronic lymphocytic leukemia (CLL).

The combination was explored in the GENUINE study, results of which were presented at the 2017 ASCO Annual Meeting. Ublituximab is a monoclonal antibody that is similar to obinutuzumab (Gazyva), Chavez explains. It has shown good activity as a single agent and also in combination with other drugs.

As seen in other clinical trials of combinations with ibrutinib, Chavez says that adding ibrutinib to a monoclonal antibody like ublituximab could lead to better outcomes.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x